|
Kidney Failure, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The risk of progression to ESRD of patients with CG II and III was significantly higher than that of patients with CG I.
|
30367317 |
2019 |
|
Chronic kidney disease stage 5
|
0.010 |
Biomarker
|
disease |
BEFREE |
The risk of progression to ESRD of patients with CG II and III was significantly higher than that of patients with CG I.
|
30367317 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We have identified two novel loci (in or near the genes KLHL7/NUPL2 and DLG2) that may play a role in COPD pathogenesis in Hispanic populations.
|
25584925 |
2015 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Diarrhea
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
By multivariate analysis, diabetes (95% confidence interval [CI]: 1.9-13.2, P< .001), prior ESBL E coli colonization (<90 days) (95% CI: 1.2-67.8, P< .001), recent receipt of antibiotics (<90 days) (95% CI: 4.2-44.2, P= .004), and previous exposure to third-generation cephalosporins (95% CI: 2.2-16.4, P= .001) and fluoroquinolones (95% CI: 1.4-18.3; P= .003) were associated risks among CG I. Diabetes (95% CI: 1.6-15.4, P= .005), stroke (95% CI: 1.5-17.1, P= .001), and diarrhea (95% CI: 3.8-65.8, P= .001) were risks among CG II.
|
17980240 |
2007 |
|
Peroxisome biogenesis disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PEX1 mutation was delineated to be the genetic cause of PBD in the most highest incidence group, CG-E (the same as CG-I).
|
11330042 |
2000 |
|
DEAFNESS, AUTOSOMAL DOMINANT 5 (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the CG1 gene in DFNA5 patients, however, could not reveal a disease-causing mutation.
|
9450185 |
1998 |
|
Hemochromatosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These new genes are located within a region that may well contain the gene responsible for hemochromatosis and have therefore been named HCG I-VII (Hemochromatosis Candidate Gene).
|
8490624 |
1993 |
|
HEMOCHROMATOSIS, TYPE 1
|
0.010 |
Biomarker
|
disease |
BEFREE |
These new genes are located within a region that may well contain the gene responsible for hemochromatosis and have therefore been named HCG I-VII (Hemochromatosis Candidate Gene).
|
8490624 |
1993 |